Calcium carbonate

What it is

Calcium carbonate is an inorganic calcium salt - chemically the same compound as chalk and limestone. As a medicine it is sold over the counter as a chewable antacid; the leading US label states "Calcium Carbonate 1000 mg" per tablet with "elemental calcium 410 mg". It neutralises acid by direct chemical reaction, and a review of self-management for reflux places that reaction mainly in the oesophagus rather than in the stomach. The same compound is sold as a calcium supplement and prescribed to people with chronic kidney disease as a phosphate binder.

What the research says

Two different jobs with two different evidence bases. As an antacid it chemically neutralises acid already in the stomach, which gives fast, short-lived relief of occasional heartburn; the reviews describe it as a reactive treatment rather than something that prevents reflux, and a modern placebo-controlled trial of calcium carbonate alone for heartburn is hard to find. As a calcium supplement its effect on fractures is genuinely disputed: a National Osteoporosis Foundation meta-analysis found a 15% reduction in total fractures with calcium plus vitamin D, while the largest single trial, the Women's Health Initiative, found no significant reduction in hip fracture and a 17% increase in kidney stones. Whether calcium supplements raise heart attack risk is an open argument between research groups.

Evidence grade: Disputed.

How it works

Drug class: Acid-neutralising antacid (an inorganic calcium salt of carbonic acid); also used as a calcium supplement and, on prescription, as a phosphate binder

Calcium carbonate works chemically, not by switching anything off. The carbonate neutralises hydrochloric acid to form chloride salts and water, which lowers the hydrogen ion concentration and raises the pH. Where that happens matters, and the review we rely on is explicit: antacids act mainly on acid that has already refluxed into the oesophagus and have only a minimal effect on acidity inside the stomach. That is why relief is fast and short - the drug removes acid that is already there rather than reducing how much is made, so it is a reactive rather than a preventive treatment. (Source 1)

What it is used for

• Approved and widely used. The acid-neutralising chemistry is not in doubt, but the best onset figure we hold - pH 3.0 within 40 seconds - comes from a manufacturer's in-vitro model of a calcium-plus-magnesium carbonate tablet, not from calcium carbonate alone and not from a person. For antacids as a class, a review reports a pooled therapeutic gain over placebo of 11% (0.11, 95% CI 0.03 to 0.20) and relief within 10 to 20 minutes, while noting the antacid trial literature is older and weaker than that for the other non-prescription options. A modern placebo-controlled trial of calcium carbonate on its own is not something we could find. Two of the sources that characterise antacids favourably are industry writing: the 40-second in-vitro study is by Bayer staff about Bayer's product, and one review calling antacids the mainstay treatment is by GSK Consumer Healthcare staff. Evidence: limited. (Source 2)
• Not an approved over-the-counter drug use - the antacid label carries no bone claim - and the evidence is contested. A National Osteoporosis Foundation meta-analysis of 8 trials found a 15% reduction in total and 30% in hip fractures with calcium plus vitamin D - figures its own authors later revised in a published erratum we could not record verbatim; the Women's Health Initiative, the largest trial, found no significant reduction in hip fracture; a 2019 meta-analysis of 6 trials found a 6% reduction in any fracture; and a 2025 meta-analysis restricted to postmenopausal women with osteoporosis found no significant reduction. Evidence: disputed. (Source 3)
• A prescribed use outside the over-the-counter antacid label. The source we hold names only this indication - it says calcium carbonate is frequently prescribed in chronic kidney disease to prevent secondary hyperparathyroidism - so phosphate binding, which calcium carbonate is also used for, is not claimed here. We did not research this use's outcome evidence in this batch; it is noted because it is one route by which people take large amounts of calcium carbonate and is named in the milk-alkali literature as a contributor to the syndrome's resurgence. Evidence: unknown. (Source 4)

Interactions

• Bictegravir (and integrase inhibitors generally) (pharmacokinetic study): Taken together on an empty stomach, calcium carbonate cut bictegravir exposure by a third. The authors explain integrase inhibitors' susceptibility to "chelation-type" interactions with metal-cation medicines, which is consistent with binding in the gut, but this study measured exposure, not binding. Giving calcium carbonate or iron with a meal, or giving bictegravir 2 hours or more before an aluminium/magnesium antacid, reduced the interaction - note that the meal is the strategy the paper pairs with calcium, and the 2-hour separation the one it pairs with the antacid. Aluminium/magnesium antacids were far worse, at 79%. (Source 5)
• Fluoroquinolone antibiotics, and calcium-fortified drinks (pharmacokinetic study): Metal cations chelate quinolones in the gut and reduce absorption, and how much depends on the cation. The review's summary sentence excepts calcium preparations from its finding that antacids and mineral supplements substantially reduce quinolone bioavailability, and its Key Points say "antacids/non-calcium mineral supplements" - calcium had the smallest effect of the antacid types it compared. In its own subgroup analysis, though, calcium supplements still lowered ciprofloxacin exposure by about 35%, and its authors advise against taking the two together. Calcium-fortified orange juice and milk also reduced absorption, milk worst for ciprofloxacin. (Source 6)
• Ciprofloxacin specifically (pharmacokinetic study): The same review's subgroup analysis is where the calcium interaction actually shows up, and only for this one quinolone: ciprofloxacin exposure fell by about 35% on average when calcium supplements were taken with it, and its authors conclude against simultaneous intake even though urinary ciprofloxacin stayed above the level needed for common urinary pathogens in one study. For the other quinolones the same review calls calcium's effect probably clinically irrelevant or clinically insignificant, and its abstract excepts calcium preparations from the general antacid and mineral-supplement finding. (Source 7)
• Levothyroxine (pharmacokinetic study): Calcium forms a complex with levothyroxine in the gut and reduces how much is absorbed, which raises TSH. A systematic review of 128 studies lists calcium and iron supplements among the documented interactions and names direct complexing and alkalisation as mechanisms, and says dose adjustment, separating the doses or stopping the interfering substance can eliminate them - its wording is that these measures can do so, not that they were observed to. (Source 8)
• Levothyroxine - the size of the effect, and a dissenting study (pharmacokinetic study): The same review's calcium section quantifies it: in a randomised crossover test in seven healthy people, levothyroxine absorption fell by 31.0% when 2.0 g of calcium carbonate was taken at the same time. The review also carries the other side - one retrospective long-term study found calcium acetate was associated with no change in TSH - and attributes the discrepancy to study design and to short against long-term effects. Its own third paragraph is the counterweight to the figure: it reasons that most calcium-treated patients stay euthyroid without any intervention, and lists dose adjustment, separating the doses, stopping the calcium, switching to another calcium product and switching to a liquid or soft-gel levothyroxine as measures that can eliminate the malabsorption. (Source 9)
• Levothyroxine - what the review says resolves it (systematic review of published interaction studies): The same review's own conclusion on this interaction is reassuring rather than alarming. It reasons that, because only a small number of calcium-treated patients have been reported with a clinically important rise in TSH, most remain euthyroid with no intervention at all. Where TSH does rise materially it names dose elevation, separating the doses or stopping the interfering medicine, switching to a different calcium product, and liquid or soft-gel levothyroxine formulations, which do not need to disintegrate, as measures that can eliminate the malabsorption. These are the review's recommendations to clinicians, not instructions to a reader. (Source 9)
• Zinc supplements and dietary zinc (pharmacokinetic study): A 600 mg calcium dose taken with a meal halved zinc absorption from that meal in a human absorption study, and a longer balance study found net zinc absorption and balance each fell by about 2 mg a day on higher calcium intake. Adding zinc to the calcium supplement cancelled the effect. (Source 10)
• Iron supplements and dietary non-haem iron (theoretical): Calcium is one of the recognised inhibitors of non-haem iron absorption, alongside phytate and polyphenols. In the bictegravir study, iron (ferrous fumarate) and calcium carbonate behaved the same way towards the drug, which is the same chelation chemistry. The iron evidence here comes from a review rather than a single quantified human trial. (Source 11)
• Food and meals (clinical trial): Food cuts both ways, on the evidence of one stable-isotope study in Nigerian children with and without rickets: fractional calcium absorption from a high-phytate maize-porridge meal was 61.3% against 27.8% without the meal, while zinc absorption fell sharply with the same meal. Separately, the bictegravir study found that giving calcium carbonate with a meal reduced its interference with that drug. (Source 12)
• Alcohol (theoretical): We found no study of a calcium carbonate / alcohol interaction. It is worth saying why the gap exists: the systematic review that catalogued food, beverage and antacid effects on drug absorption explicitly excluded alcohol studies from its scope, so this is an untested question rather than a tested negative. (Source 6)
• Prescription medicines generally (label position) (label): The label's own interaction statement is broad rather than specific: it tells people taking any prescription drug to ask a doctor or pharmacist first, because antacids may interact with certain prescription drugs. (Source 13)
• Calcium citrate as an alternative salt, after bariatric surgery (clinical trial): After Roux-en-Y gastric bypass, sleeve gastrectomy or one-anastomosis gastric bypass, a randomised double-blind crossover trial found calcium citrate slightly better absorbed than calcium carbonate and more suppressive of parathyroid hormone. The trial reports outcomes only; it offers no explanation, and it says nothing about people whose anatomy is unaltered. (Source 14)

Stopping it

• There is no withdrawal syndrome described for calcium carbonate, but stopping it is the first step in treating its most serious harm. In the reported milk-alkali case, intravenous fluids and calcitonin brought the calcium from 15.8 to 12.1 mg/dL and it normalised to 8.8 mg/dL only after intravenous furosemide on the second day; kidney function was not re-measured. (Source 15)
• The published account of management puts stopping the product first, with fluids as the mainstay and calcitonin for speed; bisphosphonates, which are used for other causes of very high calcium, are described as generally unnecessary here. (Source 16)
• For the supplementation use, one review argues there is nothing to lose by stopping because the bone-density effect does not accumulate: supplements produce small short-term density changes without a cumulative benefit. (Source 17)
• The other side of that argument is adherence: in the Women's Health Initiative, censoring the women once they stopped taking their tablets moved the hip fracture result from non-significant to significant, which is an argument that benefit depends on continuing - though a post-hoc per-protocol analysis is weaker evidence than the intention-to-treat result. (Source 18)
• For the antacid use, the label sets its own stopping rule rather than a taper: not more than 2 weeks at maximum dosage without a doctor, and not to be used for symptoms persisting beyond 2 weeks unless advised. (Source 13)

What goes wrong

A patient-level and trial-level meta-analysis found calcium supplements without vitamin D were associated with a hazard ratio of 1.31 for myocardial infarction in the patient-level analysis. (Source 19)

• Meta-analysis, Moderate certainty.
• Size: 15 trials; 5 with patient-level data (8151 participants, median follow-up 3.6 years) and 11 with trial-level data (11,921 participants, mean 4.0 years)
• Who: participants of mean age over 40 in randomised placebo-controlled trials of calcium supplements of 500 mg a day or more.
• How long: median 3.6 years (patient-level); mean 4.0 years (trial-level)
• Result: Patient-level: 143 myocardial infarctions on calcium versus 111 on placebo, hazard ratio 1.31 (95% CI 1.02 to 1.67, P=0.035). Stroke 1.20 (0.96 to 1.50, P=0.11); composite of myocardial infarction, stroke or sudden death 1.18 (1.00 to 1.39, P=0.057); death 1.09 (0.96 to 1.23, P=0.18). The separate trial-level analysis gives a pooled relative risk for myocardial infarction of 1.27 (1.01 to 1.59, P=0.038) - a different figure from a different analysis. Cardiovascular outcomes came from self-reports, hospital admissions and death certificates, not from a pre-specified adjudicated endpoint.
• Funding: grant-supported (grants list present); open access.

In the five studies contributing patient level data, 143 people allocated to calcium had a myocardial infarction compared with 111 allocated to placebo (hazard ratio 1.31, 95% confidence interval 1.02 to 1.67, P=0.035).

Milk-alkali syndrome - high blood calcium, metabolic alkalosis and acute kidney injury - commonly follows the combined intake of large amounts of calcium and absorbable alkali, and the reference text attributes its return to the common use of over-the-counter calcium preparations; it is now one of the commonest causes of high blood calcium in hospital. (Source 4)

• Expert review, not systematic, Low certainty.
• Size: not applicable.
• Who: people taking large amounts of calcium and absorbable alkali, including postmenopausal women on supplements and people with chronic kidney disease.
• How long: can be acute in onset.
• Result: Milk-alkali syndrome is stated to account for more than 10% of cases of high blood calcium and to be the third most common cause in hospitalised patients, after hyperparathyroidism and malignancy; untreated it may cause acute renal failure and metastatic calcification. The chapter defines it by the combined intake of calcium AND absorbable alkali, and calcium carbonate is itself an absorbable alkali; it attributes the modern resurgence to the common use of over-the-counter calcium preparations rather than to overuse of any one product.
• Funding: not applicable - open-access reference text.

Milk-alkali syndrome now accounts for more than 10% of the cases of hypercalcemia and is the third most common cause of hypercalcemia in hospitalized patients (after hyperparathyroidism and hypercalcemia of malignancy).

A case report describes severe high blood calcium, marked alkalosis and acute kidney injury in a man who had been taking excessive antacid for heartburn; his calcium normalised over two days on intravenous fluids and calcitonin followed by intravenous furosemide, and the abstract reports him discharged at 48 hours. (Source 20)

• Case report, Very low certainty.
• Size: 1 adult (60-year-old man)
• Who: emergency department presentation with altered mental status.
• How long: 48-hour admission.
• Result: Severe hypercalcaemia, marked metabolic alkalosis and acute kidney injury (urea 52 mg/dL, creatinine 1.27 mg/dL at presentation, the latter only marginally above the stated range). Treated with 0.9% saline at 200 mL/h and subcutaneous calcitonin; calcium fell from 15.8 to 12.1 mg/dL and normalised to 8.8 mg/dL only after intravenous furosemide on the second hospital day. Kidney function was not re-measured.
• Funding: not stated.

Limit of this finding: The abstract's "complete resolution of signs and symptoms" is not the whole picture the paper's own body gives: during the admission the patient had persistent speech slurring, an MRI showed an incidental subacute right frontal infarct, he was started on an anticoagulant for stroke prevention, and he was discharged with vitamin D deficiency and subclinical hypothyroidism needing follow-up. Only calcium was re-measured, so no claim can be made about his kidney function recovering.

A 60-year-old man with multiple comorbidities presented to the emergency department with altered mental status after his scheduled kyphoplasty was canceled due to concerning neurological findings. Laboratory evaluation revealed severe hypercalcemia, marked metabolic alkalosis, and acute kidney injury. Further history revealed excessive antacid consumption for heartburn.

A review by the research group that raised the cardiovascular signal sets the harms of calcium supplements against the benefit: a doubling of hospital admissions for gastrointestinal problems, a 17% increase in kidney stones and a 20 to 40% increase in myocardial infarction risk, all as relative increases. (Source 17)

• Expert review, not systematic, Low certainty.
• Size: not applicable - a review drawing on meta-analyses and the Auckland Calcium Study.
• Who: mostly healthy older adults taking calcium supplements.
• How long: trials of varying length, up to 5 years for the Auckland cohort.
• Result: Total fracture numbers reduced by 0 to 10% depending on the meta-analysis chosen; set against a doubling of hospital admissions for gastrointestinal problems, a 17% increase in renal calculi and a 20 to 40% increase in myocardial infarction risk.
• Funding: listed as Research Support, Non-U.S. Gov't. The authors are Reid, Bristow and Bolland - the group whose meta-analyses first raised the cardiovascular signal - so this is an interested narrative review, not an independent synthesis.

Limit of this finding: All three harm figures are relative increases and the review gives no absolute risks beside them, so a "20 to 40% increase in myocardial infarction risk" is 20 to 40% of whatever a person's underlying risk is, not 20 to 40 extra cases in a hundred people. The fracture-benefit figures in the same sentence are the same group's reading of other people's meta-analyses.

This must be balanced against an increase in gastrointestinal side effects (including a doubling of hospital admissions for these problems), a 17% increase in renal calculi and a 20-40% increase in risk of myocardial infarction.

In a phase 1 pharmacokinetic study, taking calcium carbonate at the same time as the HIV drug bictegravir on an empty stomach reduced bictegravir exposure by 33%. (Source 5)

• Blood level study, Moderate certainty.
• Size: 42 adult participants without HIV.
• Who: healthy adults, open-label single-dose crossover.
• How long: single doses.
• Result: Bictegravir area under the curve reduced by 79% with an aluminium/magnesium antacid, 33% with calcium carbonate and 63% with ferrous fumarate under fasted conditions; giving calcium carbonate or iron with a meal, or the drug 2 hours before the antacid, reduced the interaction.
• Funding: industry study of a marketed single-tablet regimen (B/F/TAF); grants list present; registered NCT05502341/NCT06333808.

BIC exposure (area under the plasma concentration-time curve extrapolated to infinity) was reduced by 79%, 33%, and 63%, respectively, when co-administered with aluminum/magnesium-containing antacid, calcium carbonate, and ferrous fumarate under fasted conditions.

A systematic review with meta-analyses of quinolone antibiotics found that antacids and mineral supplements substantially reduced the bioavailability of all 14 quinolones analysed, with calcium preparations named as the exception in that sentence and, in the review's own comparison, the smallest effect of any antacid type. (Source 6)

• Systematic review, Low certainty.
• Size: 109 studies from 101 reports, covering 22 quinolones.
• Who: human pharmacokinetic studies of orally taken quinolones with food, beverages, antacids and mineral supplements.
• How long: single-dose and before-after study designs.
• Result: The review's summary sentence reads "All 14 analysed quinolones showed a substantial reduction in bioavailability when co-administered with antacids and mineral supplements, except for calcium preparations", and its Key Points repeat the carve-out as "antacids/non-calcium mineral supplements". Aluminium and aluminium-magnesium preparations had the largest effect. Beverage data were available for 10 quinolones, of which 5 (50%) had significantly reduced absorption with milk, worst for ciprofloxacin; ciprofloxacin and levofloxacin absorption was also reduced by orange juice, particularly calcium-fortified. The review judged 46% of included studies at high risk of bias and only 4% at low risk.
• Funding: listed as Research Support, Non-U.S. Gov't.

All 14 analysed quinolones showed a substantial reduction in bioavailability when co-administered with antacids and mineral supplements, except for calcium preparations.

In the body of the same review, calcium supplements did lower ciprofloxacin exposure: its subgroup analysis found the area under the curve reduced by about 35% on average, with the effect on peak concentration varying between a significant reduction and none depending on the meta-analysis. (Source 7)

• Meta-analysis, Low certainty.
• Size: subgroup analyses by type of antacid or mineral supplement for 3 quinolones out of the 22 reviewed.
• Who: human pharmacokinetic studies of ciprofloxacin taken with calcium supplements.
• How long: single-dose and before-after study designs.
• Result: Ciprofloxacin area under the curve lower by about 35% on average with calcium supplements, against 85% with aluminium/magnesium antacids and 55% with iron; the effect on peak concentration ranged from a significant 41% reduction to no significant change. The review resolves the conflict by noting that the one neutral study was in patients with renal failure and at high risk of bias, that two others gave calcium carbonate 2 hours before the antibiotic, and that in all remaining studies absorption fell substantially. Its authors advise against taking the two at the same time. Read this against the review's own carve-out: its abstract excepts calcium preparations from the general finding that antacids and mineral supplements substantially reduce quinolone bioavailability, and the two paragraphs that follow this one judge calcium's effect probably clinically irrelevant for gemifloxacin and ofloxacin and clinically insignificant for fleroxacin, levofloxacin, lomefloxacin, moxifloxacin and nemonoxacin. Ciprofloxacin is the quinolone where it matters, and only on simultaneous intake: the review records that taking the antacid or supplement 2 hours after gemifloxacin or ofloxacin was enough to avoid the interaction.
• Funding: listed as Research Support, Non-U.S. Gov't.

Limit of this finding: This 35% figure is specific to ciprofloxacin taken at the same time as a calcium supplement. The same review excepts calcium preparations from its general statement about antacids and mineral supplements, and judges calcium's effect on the other quinolones it examined too small to matter clinically. Do not read it as a general calcium-plus-antibiotic effect, and note the underlying studies are single-dose or before-and-after pharmacokinetic studies, not trials of whether anyone's infection was cured.

Upon co-intake with calcium supplements, the decrease of AUC was lower (by on average 35%), and the effect on Cmax varied from a significant reduction (by on average 41%) to no significant changes (depending on the meta-analysis).

In a cohort of hypothyroid women, taking calcium carbonate within 2 hours of levothyroxine raised TSH and pushed 18% of them above the normal TSH range; separating the two by 6 to 8 hours restored control. (Source 21)

• Cohort study, Low certainty.
• Size: 50 postmenopausal hypothyroid women on levothyroxine, mean age 71.7 +/- 5.1 years.
• Who: women in a referral centre who added calcium supplementation of 600 to 1000 mg a day.
• How long: 2.3 +/- 1.1 years in the close-timing setting.
• Result: TSH 3.33 +/- 1.93 mU/L when calcium was taken within 2 hours of levothyroxine, versus 1.93 +/- 0.51 before calcium was added and 2.16 +/- 0.54 after the doses were separated by 6 to 8 hours (P < 0.001 for both); 18% had TSH above 4.12 mU/L in the close-timing period versus none in the others (P < 0.01). Total cholesterol, fasting glucose and blood pressure were also significantly higher in that period, though the sentence reporting their size is unusable (see the caveat). This is an observational cohort with no control group and three sequential periods, so secular change cannot be excluded.
• Funding: not stated.

Limit of this finding: The source's own Results sentence garbles its units: it reports that total cholesterol, glucose and systolic and diastolic blood pressure "increased by 12.1, 3.12 mg/dL, 2.31, and 2.0 mmHg, respectively", attaching mg/dL only to the second figure and mmHg only to the fourth and leaving two of the four without a unit. Those four numbers should not be read off that sentence. The recorded passage also keeps the paper's typo "calcium supplemaentation" exactly as printed.

TSH levels were 3.33 ± 1.93 mU/L versus 1.93 ± 0.51 or 2.16 ± 0.54 comparing setting 2 with setting 1 or 3 (P < 0.001, both). In setting 2, 18% women had elevated TSH versus none in setting 1 or 3 (P < 0.01).

A 600 mg calcium supplement taken with a meal halved zinc absorption from that meal, and sustained higher calcium intake reduced net zinc absorption and balance by about 2 mg a day. (Source 10)

• Blood level study, Low certainty.
• Size: 18 postmenopausal women aged 59 to 86 in the balance study, plus a separate group of men and women aged 21 to 69 in the absorption test.
• Who: relatively healthy adults on a standardised diet.
• How long: 36-day balance study; single test meal for the absorption test.
• Result: Net zinc absorption and zinc balance were significantly reduced by about 2 mg a day on both high-calcium treatments (milk or inorganic calcium phosphate, an extra 468 mg calcium a day). In the acute test, a 600 mg calcium supplement as calcium carbonate given with a meal reduced zinc absorption by 50%; adding 7.8 mg of zinc to the supplement offset the effect.
• Funding: listed as Research Support, Non-U.S. Gov't and Research Support, U.S. Gov't, Non-P.H.S.

Zinc absorption was reduced significantly by 50% when the calcium supplement was given with the meal. Inclusion of an extra 119.3 mumol (7.8 mg) Zn as part of a calcium supplement offset the detrimental effect of calcium on zinc absorption.

The same US label discloses, in a second "Other information" section covering the tropical-fruit and assorted-fruit versions, that those tablets contain FD&C Yellow No. 5 (tartrazine) as a colour additive. (Source 22)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: US over-the-counter users of the flavoured versions of this product.
• How long: label version 21, published 30 September 2026.
• Result: The disclosure appears only in the second of the label's two near-identically headed "Other information" sections; the first repeats the same tablet-content and storage lines without it. Three of the label's five inactive-ingredient lists also name FD&C yellow #5 (tartrazine) lake. Tartrazine is a declared colour additive that some people react to, which is why the label names it.
• Funding: not applicable - manufacturer-submitted labelling.

each tablet contains:elemental calcium 410 mg, magnesium 5 mg, sodium 2mg store below 30 oC (86 oF) contains FD&C Yellow No. 5 (tartrazine) as a color additive

What the evidence supports

In a manufacturer's in-vitro stomach model, a calcium-plus-magnesium-carbonate antacid tablet raised the pH of the simulated gastric medium to 3.0 within 40 seconds and reduced pepsin activity while the pH stayed up. (Source 2)

• Lab study in cells, Very low certainty.
• Size: six independent 2-hour stomach incubations per arm, two tablets per incubation.
• Who: not human - a validated simulator of the human gastrointestinal tract.
• How long: 2-hour gastric incubations.
• Result: pH 3.0 reached within 40 s; maximum pH 5.24 maintained for almost 10 minutes; with placebo the maximum pH was 1.28 throughout.
• Funding: industry: the first and corresponding author's affiliation is Bayer Consumer Care AG, Basel, the second author is a medical-writing agency, and the product tested, Rennie, is Bayer's own. No funding statement was reachable.

Limit of this finding: This is a company study of the company's own product, and its conclusions read promotionally. The apparatus is a gut-microbiome simulator used here as a stomach model, so the figure is a reactor measurement, not a measurement in a person. And the tablet combines calcium carbonate with magnesium carbonate, so the 40-second figure cannot be carried as evidence for calcium carbonate on its own.

After addition of Rennie, the gastric medium reached a pH of 3.0 within 40 s. The maximum pH of 5.24 was maintained for almost 10 min. In contrast, the maximum pH with placebo was 1.28 during the entire gastric simulation. Furthermore, Rennie strongly reduced the activity of mucosa-damaging pepsin during the period of increased pH.

A review of non-prescription reflux treatment reports that, pooling randomised trials, antacids gave a therapeutic gain over placebo of 11%, and that the quantity and quality of antacid studies is inferior to that for the other non-prescription options. (Source 1)

• Expert review, not systematic, Low certainty.
• Size: not stated in the review: a pooled estimate from randomised controlled trials of antacids as a class.
• Who: adults self-treating reflux-like symptoms.
• How long: not applicable.
• Result: Therapeutic gain relative to placebo 11% (0.11, 95% CI 0.03 to 0.20), an interval that excludes zero. Patients report meaningful heartburn improvement within 10 to 20 minutes. The same review records that a meta-analysis found the quantity and quality of antacid studies inferior to those for the other products, most likely because most antacid research was done long ago. This is antacids as a class, not calcium carbonate specifically, and the figure is quoted from a review rather than from the meta-analysis itself.
• Funding: industry-funded: the online meetings this review was built from were organised by Lumanity and funded by Reckitt Benckiser Healthcare Ltd, the writing support was funded by the same company, and all eight authors declare Reckitt consulting, speaking or advisory relationships. The review states the funder had no role in conception, planning, writing or the decision to publish.

Limit of this finding: Who paid matters here. Reckitt Benckiser Healthcare Ltd funded the meetings behind this review and the writing of it, and Reckitt sells the alginate product that the same review rates above antacids - including on the pepsin comparison. The 11% therapeutic gain and the judgement that the antacid trial literature is weaker than the literature for the other products therefore come from a source with a commercial interest in that ranking. The figure is the review's quotation of a meta-analysis, not its own calculation, and we could not read that meta-analysis ourselves.

Using data from randomized controlled trials (RCTs), the therapeutic gain relative to placebo was 11% (0.11 [95% CI: 0.03–0.20]).

A National Osteoporosis Foundation meta-analysis of randomised trials found calcium plus vitamin D reduced total fractures by 15% and hip fractures by 30%. (Source 3)

• Meta-analysis, Moderate certainty.
• Size: 8 studies, 30,970 participants, 195 hip fractures and 2231 total fractures.
• Who: community-dwelling and institutionalised middle-aged to older adults.
• How long: varies by trial.
• Result: Total fractures summary relative risk 0.85 (95% CI 0.73 to 0.98); hip fractures 0.70 (95% CI 0.56 to 0.87). The authors state as a limitation that the analysis used data from a subgroup analysis of the Women's Health Initiative.
• Funding: listed as Research Support, Non-U.S. Gov't; the analysis was conducted for the National Osteoporosis Foundation, which should be read as an interested party.

Limit of this finding: A published erratum follows this paper and we could not incorporate it. PubMed's record carries 'Erratum and additional analyses re: Calcium plus vitamin D supplementation and the risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation' by the same authors (Osteoporos Int 2016;27(8):2643-2646, doi 10.1007/s00198-016-3699-z, PMID 27401092), in which they revised these pooled estimates after errors in their Table 1. The 15% and 30% reductions quoted here are the original paper's, and should be read as the authors' first estimates rather than their final ones. We could reach the erratum's record on two registries but could only open its text on a route that caps how much may be reproduced, so no revised figure is quoted anywhere in this entry and a reviewer with journal access should check it before these two percentages are shown.

Meta-analysis of all studies showed that calcium plus vitamin D supplementation produced a statistically significant 15 % reduced risk of total fractures (SRRE, 0.85; 95 % confidence interval [CI], 0.73-0.98) and a 30 % reduced risk of hip fractures (SRRE, 0.70; 95 % CI, 0.56-0.87).

In the same case the published management was to stop the calcium-containing product and give fluids, with calcitonin for speed and a loop diuretic only after rehydration; the authors state bisphosphonates are generally unnecessary in milk-alkali syndrome. (Source 16)

• Case report, Very low certainty.
• Size: 1 adult (60-year-old man)
• Who: emergency presentation with milk-alkali syndrome.
• How long: 48-hour admission.
• Result: Immediate discontinuation of calcium-containing products is described as the most crucial intervention; intravenous hydration as the cornerstone; calcitonin as rapid but temporary, acting within four to six hours; loop diuretics only after adequate volume resuscitation; bisphosphonates generally unnecessary. This is one case report's account of management, not a trial of it.
• Funding: the authors disclosed no conflicts of interest.

Bisphosphonates are generally unnecessary given the rapid response to conservative measures, unlike other causes of severe hypercalcemia.

In Nigerian children with and without nutritional rickets, fractional calcium absorption measured with stable isotopes was more than twice as high when the dose was given with a high-phytate maize-porridge meal as without it, while zinc absorption moved the other way. (Source 12)

• Randomized trial, Low certainty.
• Size: 19 children with rickets and 15 age-matched controls, aged 2 to 10 years.
• Who: 19 Nigerian children with nutritional rickets and 15 age-matched controls, aged 2 to 10 years, all of whom had already been given calcium 600 mg a day and ergocalciferol for 6 weeks before the measurements; the test meal was specifically a high-phytate maize porridge.
• How long: absorption measured after 6 weeks, repeated a week later.
• Result: Calcium absorption 61.3 +/- 25.1% with the maize-porridge meal versus 27.8 +/- 14.6% without (P < 0.001); zinc absorption 16.2 +/- 8.0% with a meal versus 63.4 +/- 23.9% without (P < 0.001). The +/- figures are standard deviations, not confidence intervals, and they are wide relative to the difference.
• Funding: NIH-supported (listed as Research Support, N.I.H., Extramural)

Limit of this finding: This is a difference between two group means in 34 vitamin-D-repleted, calcium-deficient children against one high-phytate test meal, with heavily overlapping spreads. It should not be read as a general rule about taking a calcium supplement with food, nor as the effect any one person would get.

Calcium absorption was greater with a meal (61.3 +/- 25.1%) than without (27.8 +/- 14.6%; P < 0.001). Zinc absorption was lower with a meal (16.2 +/- 8.0%) than without (63.4 +/- 23.9%; P < 0.001).

The US Drug Facts label for the 1000 mg calcium carbonate antacid caps use at 7 tablets in 24 hours, 5 if pregnant, and no more than 2 weeks at maximum dosage without medical supervision. (Source 13)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: US over-the-counter users aged 12 and over.
• How long: label version 21, published 30 September 2026.
• Result: Each tablet contains calcium carbonate 1000 mg and elemental calcium 410 mg; label limits are 7 tablets in 24 hours, 5 in pregnancy, and 2 weeks at maximum dosage.
• Funding: not applicable - manufacturer-submitted labelling.

do not take more than 7 tablets in 24 hours if pregnant do not take more than 5 tablets in 24 hours do not use the maximum dosage for more than 2 weeks, except under the advice and supervision of a doctor

What the evidence does not support

The clinical-trial evidence specifically for calcium carbonate as a heartburn treatment is weak: the closest study we found was a prospective single-arm, uncontrolled, open-label study of a combination tablet. (Source 23)

• Case series, Very low certainty.
• Size: 100 adults.
• Who: adults with symptomatic heartburn, acid regurgitation or recurrent acid-related gastric discomfort; a single-arm open-label study with no control group and no blinding, indexed as a clinical trial but not randomised.
• How long: up to 4 weeks of as-needed use, up to four tablets a day.
• Result: 81 of 100 participants reported first symptom relief within 20 minutes in at least half of their uses, and 83 of 100 reported effects lasting more than 120 minutes; heartburn frequency and intensity fell over 4 weeks (p < 0.0001). There was no control group and no blinding, and the tablet combined calcium carbonate and magnesium carbonate with a cactus extract, so none of the effect can be attributed to calcium carbonate alone.
• Funding: not stated in the abstract; a named branded product was studied.

Limit of this finding: We record this as a case-series because our design list has no value for a single-arm, uncontrolled, open-label trial; the paper's own description, "a prospective, clinical, uncontrolled, open-label study", is quoted so the real design travels with it.

To investigate performance and safety of Refluthin in the rapid and long lasting relief of heartburn and acid related gastric discomfort under practical use conditions, a prospective, clinical, uncontrolled, open-label study was conducted.

In the Women's Health Initiative, 1000 mg of calcium as calcium carbonate with vitamin D did not significantly reduce hip fracture over 7 years, and increased kidney stones. (Source 18)

• Randomized trial, High certainty.
• Size: 36,282 postmenopausal women aged 50 to 79.
• Who: healthy postmenopausal women already enrolled in a Women's Health Initiative clinical trial.
• How long: average follow-up 7.0 years.
• Result: Hip fracture hazard ratio 0.88 (95% CI 0.72 to 1.08); clinical spine fracture 0.90 (0.74 to 1.10); total fractures 0.96 (0.91 to 1.02); hip bone density 1.06% higher (P<0.01); renal calculi hazard ratio 1.17 (95% CI 1.02 to 1.34). Censoring non-adherent women lowered the hip fracture hazard ratio to 0.71 (0.52 to 0.97).
• Funding: NIH-supported (listed as Research Support, N.I.H., Extramural); ClinicalTrials.gov NCT00000611.

Among healthy postmenopausal women, calcium with vitamin D supplementation resulted in a small but significant improvement in hip bone density, did not significantly reduce hip fracture, and increased the risk of kidney stones.

A 2025 systematic review and meta-analysis restricted to postmenopausal women with osteoporosis found calcium plus vitamin D did not reduce clinical fracture risk. (Source 24)

• Meta-analysis, Moderate certainty.
• Size: 11 randomised controlled trials with 43,869 participants in total.
• Who: postmenopausal women with osteoporosis.
• How long: varies by trial; no dose-response effect was found for duration.
• Result: Overall fracture risk RR 0.98 (95% CI 0.89 to 1.07, p = 0.68). Bone mineral density improved modestly at the pelvis (SMD 0.20, 95% CI 0.05 to 0.35, p = 0.01), with no significant change at lumbar spine, femoral neck or total hip; three large trials contributing more than 42,000 participants gave a pooled fracture RR of 0.95 (95% CI 0.85 to 1.07, P = 0.28, I2 = 0%). The authors call for larger trials with adjudicated fracture endpoints.
• Funding: not stated.

Limit of this finding: Two cautions, both internal to the paper. It prints an overall fracture RR of 0.98 and, two sentences later, a pooled RR of 0.95 from three trials that supply more than 42,000 of its 43,869 participants; those two numbers cannot be independent corroboration of each other, and the discrepancy is the paper's, not a transcription error. And because those three trials supply nearly all the participants, under 1,900 people are left across the remaining eight trials, so the pelvic bone-density result rests on a small fraction of the headline sample size.

The overall fracture risk was not significantly reduced (RR = 0.98, 95% CI: 0.89–1.07, p = 0.68).

A later meta-analysis of the same kind of trials found no significant excess cardiovascular risk from calcium supplements, and set an upper bound on any excess. (Source 25)

• Meta-analysis, Moderate certainty.
• Size: 11 trials: 7 comparisons of calcium alone (n = 8634) and 6 of calcium plus vitamin D (n = 46,804)
• Who: participants of placebo-controlled randomised trials of calcium supplements with or without vitamin D.
• How long: varies by trial.
• Result: Calcium alone (mean 1 g a day): myocardial infarction relative risk 1.15 (95% CI 0.88 to 1.51, 219 events); coronary heart disease death 1.24 (0.89 to 1.73, 142); any coronary heart disease 1.01 (0.75 to 1.37, 177); stroke 1.15 (0.90 to 1.46, 275). Calcium plus vitamin D: myocardial infarction 1.09 (0.95 to 1.25, 854 events); stroke 1.02 (0.89 to 1.17, 885). The authors state the analysis excluded excess risks above 0.3% to 0.5% per year.
• Funding: grant-supported (grants list present)

Limit of this finding: Every interval in this analysis crosses 1, including the largest point estimate, 1.24 for coronary heart disease death, so none of them is a demonstrated difference in either direction. One estimate, the stroke result for calcium alone, is printed with commas where the other five use a colon and semicolons - "(RR, 1.15; 95% CI, 0.90, 1.46, n = 275)". That punctuation is the source's and is reproduced unchanged.

This meta-analysis demonstrated that calcium supplements were not associated with any significant hazard for CHD, stroke, or all-cause mortality and excluded excess risks above 0.3%-0.5% per year for CHD or stroke.

The same review found calcium's effect on quinolone absorption much smaller than aluminium's or iron's, and too small to matter clinically for every quinolone it examined except ciprofloxacin. (Source 7)

• Meta-analysis, Low certainty.
• Size: subgroup and individual-study analyses within a review of 22 quinolones.
• Who: human pharmacokinetic studies of quinolones taken with antacids or mineral supplements.
• How long: single-dose and before-after study designs.
• Result: For gemifloxacin and ofloxacin the review judged calcium's effect probably clinically irrelevant while aluminium-magnesium and iron preparations given at the same time had a clinically significant negative effect. For fleroxacin, levofloxacin, lomefloxacin, moxifloxacin and nemonoxacin it reports that calcium supplements generally caused a much smaller, clinically insignificant decrease than aluminium and aluminium-magnesium antacids, and explains it by the weaker chelate calcium forms. Only norfloxacin and sitafloxacin had impaired absorption whatever the antacid type, and for all the antacids and supplements it examined, giving them 2 hours after gemifloxacin or ofloxacin avoided the interaction.
• Funding: listed as Research Support, Non-U.S. Gov't; the record also names a Jagiellonian University grant.

Limit of this finding: This is a failure to find a clinically meaningful effect in pharmacokinetic studies, not evidence that taking the two together is safe for every quinolone: the same review found a substantial effect for ciprofloxacin and advises against simultaneous intake there. The source prints 'antiacids' in this passage; that is its own typo.

For both gemifloxacin and ofloxacin, aluminium-magnesium and iron preparations given together with antibiotics exerted a clinically significant negative effect on bioavailability, whereas a probably clinically irrelevant effect occurred for calcium preparations.

An expert panel convened by the National Osteoporosis Foundation and the American Society for Preventive Cardiology adopted the position that there is moderate-quality (B level) evidence of no relationship, beneficial or harmful, between calcium intake and cardiovascular risk in generally healthy adults "at this time". (Source 26)

• Official position, Moderate certainty.
• Size: not applicable - expert panel with a commissioned evidence report from Tufts University.
• Who: generally healthy adults.
• How long: guideline issued 2016.
• Result: Graded moderate-quality (B level) evidence of no relationship with cardiovascular or cerebrovascular disease, mortality or all-cause mortality, and intake that does not exceed the National Academy of Medicine tolerable upper level of 2000 to 2500 mg a day considered safe from a cardiovascular standpoint. This is a declared position from an expert panel working from a commissioned evidence report, not a measured null, and the panel was convened by two interested professional bodies.
• Funding: convened by the National Osteoporosis Foundation and the American Society for Preventive Cardiology; both are interested parties.

The National Osteoporosis Foundation and American Society for Preventive Cardiology adopt the position that there is moderate-quality evidence (B level) that calcium with or without vitamin D intake from food or supplements has no relationship (beneficial or harmful) to the risk for cardiovascular and cerebrovascular disease, mortality, or all-cause mortality in generally healthy adults at this time.

Where the evidence is mixed

A review of non-prescription reflux treatment places antacids as neutralising refluxed acid in the oesophagus and giving temporary relief of occasional heartburn - a reactive treatment rather than a preventive one. (Source 27)

• Expert review, not systematic, Low certainty.
• Size: not applicable.
• Who: adults self-treating reflux-like symptoms.
• How long: not applicable.
• Result: Antacids are characterised as reactive rather than preventive; H2 blockers act within 30 minutes and last up to 12 hours but develop tachyphylaxis; non-prescription proton pump inhibitors are described as most effective for preventing frequent acid-related symptoms.
• Funding: not stated.

Antacids neutralize refluxed acid in the esophagus, providing temporary relief from occasional heartburn.

A 2019 systematic review and meta-analysis found vitamin D alone did not reduce fracture, while vitamin D combined with calcium reduced any fracture by 6% and hip fracture by 16%. (Source 28)

• Meta-analysis, Moderate certainty.
• Size: 6 randomised trials of combined supplementation, 49,282 participants, 5449 fractures, 730 hip fractures (plus 11 trials of vitamin D alone, 34,243 participants)
• Who: adults in randomised trials, mostly older.
• How long: varies by trial.
• Result: Vitamin D alone: any fracture rate ratio 1.06 (95% CI 0.98 to 1.14), hip fracture 1.14 (0.98 to 1.32). Vitamin D 400-800 IU plus calcium 1000-1200 mg daily: any fracture 0.94 (0.89 to 0.99), hip fracture 0.84 (0.72 to 0.97).
• Funding: grant-supported (grants list present)

In contrast, a meta-analysis of 6 RCTs (49 282 participants, 5449 fractures, 730 hip fractures) of combined supplementation with vitamin D (daily doses of 400-800 IU, yielding a median difference in 25[OH]D concentration of 9.2 ng/mL) and calcium (daily doses of 1000-1200 mg) found a 6% reduced risk of any fracture (RR, 0.94; 95% CI, 0.89-0.99) and a 16% reduced risk of hip fracture (RR, 0.84; 95% CI, 0.72-0.97).

In a double-blind randomised crossover trial after bariatric surgery, calcium citrate was absorbed slightly better than calcium carbonate and suppressed parathyroid hormone more. (Source 14)

• Randomized trial, Low certainty.
• Size: 150 participants, 50 in each of three surgery groups; 128 (85.3%) female, mean age 40.5 +/- 7.6 years.
• Who: adults a mean of 9.8 months after Roux-en-Y gastric bypass, sleeve gastrectomy or one-anastomosis gastric bypass at a single bariatric centre; nothing here speaks to people with unaltered anatomy.
• How long: 8 hours of testing per arm, crossover.
• Result: Calcium citrate gave a higher 8-hour area under the curve (76.1 versus 74.7 mg/dL*h, P = .001) and higher peak (9.8 versus 9.5 mg/dL, P < .001) than carbonate, and greater 9-hour urinary calcium (83.7 versus 68.6 mg/dL, P < .001), with greater parathyroid hormone suppression from 3 to 6 hours (P < .001). The absolute differences in serum measures are small.
• Funding: not stated.

Limit of this finding: Three things the source prints that a reader should know. Its Methods say absorption was compared over 8 hours and its Results then report urinary calcium "over 9 hours" - the inconsistency is the journal's and has not been harmonised. Its urinary calcium figures are given in mg/dL, a concentration rather than an amount excreted, which cannot be right for an excretion over a time window. And the serum differences the abstract calls "significantly better" are 1.9% on area under the curve and 3.2% on peak - statistically significant, not necessarily clinically meaningful.

Ca citrate also demonstrated superior relative bioavailability, as evidenced by a higher AUC0-8h of 76.1 mg/dL·h versus 74.7 mg/dL·h for carbonate (P = .001) and a Cmax of 9.8 mg/dL compared to 9.5 mg/dL for carbonate (P < .001).

Where the research disagrees

Whether calcium supplements increase the risk of myocardial infarction

• Bolland and colleagues (University of Auckland), authors of the 2010 meta-analysis, patient-level and trial-level meta-analysis of 15 randomised placebo-controlled trials; cardiovascular outcomes taken from self-reports, hospital admissions and death certificates rather than a pre-specified adjudicated endpoint: "Calcium supplements (without coadministered vitamin D) are associated with an increased risk of myocardial infarction. As calcium supplements are widely used these modest increases in risk of cardiovascular disease might translate into a large burden of disease in the population. A reassessment of the role of calcium supplements in the management of osteoporosis is warranted." (Source 19)
• Authors of a 2023 meta-analysis of all placebo-controlled randomised trials, fixed-effects meta-analysis of 11 placebo-controlled randomised trials, 7 of calcium alone (n = 8634) and 6 of calcium plus vitamin D (n = 46,804): "Among trials of calcium alone (mean daily dose 1 g), calcium was not significantly associated with any excess risk of MI (RR, 1.15; 95% CI: 0.88, 1.51; n = 219 events), CHD death (RR, 1.24; 95% CI: 0.89, 1.73; n = 142), any CHD (RR, 1.01; 95% CI: 0.75, 1.37; n = 177), or stroke (RR, 1.15; 95% CI, 0.90, 1.46, n = 275)." (Source 25)
• National Osteoporosis Foundation and American Society for Preventive Cardiology expert panel, clinical guideline from an expert panel, based on a commissioned evidence report; graded as moderate-quality (B level) evidence; convened by two interested professional bodies: "In light of the evidence available to date, calcium intake from food and supplements that does not exceed the tolerable upper level of intake (defined by the National Academy of Medicine as 2000 to 2500 mg/d) should be considered safe from a cardiovascular standpoint." (Source 26)

Whether calcium (with vitamin D) prevents fractures

• National Osteoporosis Foundation meta-analysis (Weaver and colleagues), random-effects meta-analysis of 8 randomised trials, 30,970 participants; the authors note it used data from a subgroup analysis of the Women's Health Initiative; superseded in part by the authors' own published erratum and additional analyses (Osteoporos Int 2016;27(8):2643-2646, PMID 27401092), which we could not record verbatim: "This meta-analysis of RCTs supports the use of calcium plus vitamin D supplements as an intervention for fracture risk reduction in both community-dwelling and institutionalized middle-aged to older adults." (Source 3)
• The Women's Health Initiative investigators, randomised, placebo-controlled, multicentre trial in 36,282 postmenopausal women with 7 years average follow-up - the largest single trial of this question: "Intention-to-treat analysis indicated that participants receiving calcium plus vitamin D supplementation had a hazard ratio of 0.88 for hip fracture (95 percent confidence interval, 0.72 to 1.08), 0.90 for clinical spine fracture (0.74 to 1.10), and 0.96 for total fractures (0.91 to 1.02)." (Source 18)
• Reid, Bristow and Bolland (University of Auckland), narrative review drawing on published meta-analyses and the Auckland Calcium Study, written by the group that raised the cardiovascular signal; its harm figures are relative increases with no absolute risks given: "As a result, anti-fracture efficacy remains unproven, with no evidence to support hip fracture prevention (other than in a cohort with severe vitamin D deficiency) and total fracture numbers are reduced by 0-10%, depending on which meta-analysis is considered." (Source 17)
• Authors of a 2019 systematic review and meta-analysis, fixed-effects meta-analysis of 6 randomised trials of combined supplementation, 49,282 participants and 5449 fractures: "In this systematic review and meta-analysis, neither intermittent nor daily dosing with standard doses of vitamin D alone was associated with reduced risk of fracture, but daily supplementation with both vitamin D and calcium was a more promising strategy." (Source 28)

Who paid for the evidence that antacids work quickly, what that evidence is, and who paid for the review that calls it weak

• Voropaiev and Nock, writing from Bayer Consumer Care AG about Bayer's own product, in-vitro study in a gut-microbiome simulator used as a stomach model, six 2-hour incubations per arm, testing a calcium-plus-magnesium-carbonate tablet, written by the manufacturer's own staff with a medical-writing agency as second author: "After addition of Rennie, the gastric medium reached a pH of 3.0 within 40 s. The maximum pH of 5.24 was maintained for almost 10 min. In contrast, the maximum pH with placebo was 1.28 during the entire gastric simulation." (Source 2)
• Garg, Narang and Taneja, writing from GSK Consumer Healthcare, narrative review with no stated search method, written by Medical Innovation Director and Medical Affairs staff of GSK Consumer Healthcare, a manufacturer of antacid products: "Despite the availability of several treatment options, antacids remain the mainstay treatment for gastroesophageal reflux-related symptoms based on their efficacy, safety, and over-the-counter availability." (Source 29)
• Authors of a 2026 review of non-prescription reflux treatment, itself funded by Reckitt Benckiser, narrative review with no stated search method; it reports a pooled therapeutic gain over placebo of 11% (0.11, 95% CI 0.03 to 0.20) for antacids as a class. Not an independent voice either: the meetings behind it and its writing support were funded by Reckitt Benckiser Healthcare Ltd, which markets the alginate this review prefers to antacids, and all eight authors declare Reckitt relationships: "A meta-analysis to assess the efficacy of OTC treatments for reflux-like symptoms found the quantity and quality of studies for antacids inferior to those for the other products, most likely because the bulk of antacid research was conducted long ago." (Source 1)
• The 2026 review's own funding and conflict-of-interest statements, the review's own declarations: the Conflict of Interest Statement opens by recording that all eight authors attended Reckitt-funded online meetings 'which formed the basis for this work', and the Funding Sources section adds that the funder had no role in conception, planning, writing or the decision to publish: "The online meetings were organized by Lumanity, UK, and funded by Reckitt Benckiser Healthcare Ltd. Writing support was provided by Lisa O’Rourke, PhD, for Lumanity, UK, and funded by Reckitt Benckiser Healthcare Ltd." (Source 30)

How much

• Reference intake: For the antacid use the amount is set by the Drug Facts label, not a prescriber. The leading US label (version 21, published 30 September 2026) states "Calcium Carbonate 1000 mg" per tablet and "elemental calcium 410 mg" per tablet, directs adults and children 12 and over to chew 2 to 3 tablets as symptoms occur or as directed by a doctor, and caps use at 7 tablets in 24 hours, 5 if pregnant, and no more than 2 weeks at maximum dosage without a doctor's advice and supervision. (Source 13)
• Upper limit: For total calcium intake from food and supplements, the National Osteoporosis Foundation and American Society for Preventive Cardiology guideline cites the National Academy of Medicine tolerable upper level of intake as 2000 to 2500 mg a day and says intake that does not exceed it should be considered safe from a cardiovascular standpoint. That is a guideline position about total intake, not a maximum for this medicine; the label's own ceiling for the antacid use is recorded above. No NIH reference intake for calcium is asserted anywhere in this entry, because the NIH Office of Dietary Supplements page was unreachable. (Source 26)
• Studied: The Women's Health Initiative trial gave 1000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily, or placebo, for an average of 7 years. (Source 18)
• Studied: In the 2019 fracture meta-analysis, the 6 trials of combined supplementation gave calcium 1000 to 1200 mg a day with vitamin D 400 to 800 IU a day. Its other 11 randomised trials tested vitamin D alone, at daily or intermittent doses of 400 to 30,000 IU and with no calcium at all. (Source 28)
• Studied: The myocardial-infarction meta-analysis included placebo-controlled trials of calcium supplements at 500 mg a day or more, and reported its dose-response analysis in fifths from under 500 to 1100 mg a day or more. (Source 19)
• Studied: The zinc-absorption experiment used a single 600 mg calcium supplement as calcium carbonate given with a test meal, and a balance study adding 468 mg calcium a day. (Source 10)
• Studied: The bariatric crossover trial compared calcium citrate against calcium carbonate over 8 hours of testing. The abstract does not state the dose in mg. (Source 14)
• Studied: In the 2023 cardiovascular meta-analysis, the trials of calcium alone used a mean daily dose of 1 g. (Source 25)

A common belief, and what the research shows

The belief: Antacid tablets are just chalk, so you can take as many as you like for as long as you like.

What the research shows: Overuse causes a real syndrome. A reference text states that "Milk-alkali syndrome is characterized by a triad of elevated calcium levels, metabolic alkalosis, and acute kidney injury that commonly occurs due to the combined intake of large amounts of calcium and absorbable alkali" and that it "now accounts for more than 10% of the cases of hypercalcemia and is the third most common cause of hypercalcemia in hospitalized patients (after hyperparathyroidism and hypercalcemia of malignancy)." The label itself sets limits: "do not take more than 7 tablets in 24 hours" and "do not use the maximum dosage for more than 2 weeks, except under the advice and supervision of a doctor".

Questions and answers

What is it?

Calcium carbonate is an inorganic calcium salt - chemically the same compound as chalk and limestone. In an over-the-counter antacid it is the whole active ingredient: the leading US label lists calcium carbonate 1000 mg per tablet, of which 410 mg is elemental calcium. The same compound is sold as a calcium supplement and prescribed as a phosphate binder in kidney disease. (Source 13)

What does it do in the body?

It neutralises acid by direct chemical reaction: the carbonate converts hydrochloric acid to chloride salts and water, lowering the hydrogen ion concentration and raising the pH. The review we rely on places that action mainly in the oesophagus, on acid that has already refluxed, and says the effect on acidity inside the stomach is minimal. That is why relief comes within minutes and then fades - the drug removes acid already there rather than reducing how much is made. Absorbed calcium also enters the body's calcium pool, which is the basis of the supplement use and of the harms at high intake. (Source 1)

Is it good or bad for you?

Good in small, occasional amounts for heartburn; harmful in large or sustained amounts. The dividing line is clear in the literature: repeated heavy use causes milk-alkali syndrome, with high blood calcium, metabolic alkalosis and acute kidney injury, which is now the third most common cause of high blood calcium in hospitalised patients. In the Women's Health Initiative, 1000 mg of calcium as carbonate with vitamin D also increased kidney stones by 17% in relative terms (hazard ratio 1.17, 95% CI 1.02 to 1.34). (Source 18)

How do you get more of it?

Dairy products are the main natural source of absorbable calcium in most diets. Food also changes how much of a dose is absorbed: in one stable-isotope study in Nigerian children, fractional absorption was 61.3% with a maize-porridge meal against 27.8% without - a large difference, but measured in 34 children against one high-phytate test meal, so not a general rule. For the medicine itself, the label directs adults and children 12 and over to chew 2 to 3 tablets as symptoms occur, with ceilings of 7 tablets in 24 hours and 2 weeks of maximum dosing. That is a description of the label, not advice. (Source 12)

If it is harmful, what reduces it?

When calcium carbonate has caused harm, the published treatment starts with stopping it. In the reported milk-alkali case the account is: stop the product, give intravenous fluids, add calcitonin for a rapid but temporary fall, and use a loop diuretic only after rehydration - which is what finally normalised that patient's calcium. The same authors say bisphosphonates, used for other causes of very high calcium, are generally unnecessary here because the response to conservative measures is quick. (Source 16)

Why might someone be low in it or missing it?

Absorption is not the same in everyone. After bariatric surgery, a randomised double-blind crossover trial in 150 people found calcium citrate slightly better absorbed than calcium carbonate and more suppressive of parathyroid hormone - the clinical shape of the problem, although the trial offers no explanation for it and says nothing about unaltered anatomy. Several common medicines also change calcium handling, and dietary phytate reduces absorption. (Source 14)

Which whole foods contain it or feed it?

Dairy foods are the main dietary source of absorbable calcium, and milk behaves like a calcium supplement in drug-interaction studies: of the 10 quinolone antibiotics for which beverage data existed, 5 had significantly reduced absorption with milk, ciprofloxacin worst. Plant foods high in phytate reduce calcium absorption. In the Nigerian isotope study, giving calcium with maize porridge raised calcium absorption but cut zinc absorption, so food effects run in both directions. (Source 6)

What happens if you do not have it?

Two different answers. Not taking the antacid simply means no fast neutralisation of occasional heartburn; the reviews put antacids as a reactive treatment, with proton pump inhibitors more effective for frequent symptoms. Not taking a calcium supplement is where the dispute lies: one meta-analysis found 15% fewer total and 30% fewer hip fractures with calcium plus vitamin D, while the largest single trial found no significant hip fracture reduction. Severe dietary calcium insufficiency is a different matter again - it causes nutritional rickets in children. (Source 12)

How can you test for it?

There is no test of calcium intake; what the literature measures is consequences. In the published cases of high calcium from antacids, the work-up used to exclude other causes was parathyroid hormone, vitamin D, a myeloma screen and imaging. A normal blood calcium does not tell you whether calcium intake is adequate, because the body defends blood calcium at the expense of bone. (Source 31)

We searched: Europe PMC searches for calcium status assessment, fractional calcium absorption, serum calcium and dietary adequacy, and the milk-alkali case reports and reference chapter; no validated test of calcium intake or status emerged, and the stable-isotope method we found is a research technique, not a clinical test.

References

1. Digestive Diseases. Self-Management of Reflux-Like Symptoms: A Patient-Centered Decision-Making Approach - the Antacids subsection's 'Mechanism of Action' and 'Efficacy' sections, held whole and in document order; the source's own figure cross-reference is kept, its numeric citation markers are not. 2026. PMID 41875283, DOI 10.1159/000551414. Read the source
2. BMC gastroenterology. Onset of acid-neutralizing action of a calcium/magnesium carbonate-based antacid using an artificial stomach model: an in vitro evaluation. 2021. PMID 33676393, DOI 10.1186/s12876-021-01687-8. Read the source
3. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation (the PubMed-rendered abstract; a published erratum with additional analyses follows at PMID 27401092). 2016. PMID 26510847, DOI 10.1007/s00198-015-3386-5. Read the source
4. StatPearls Publishing (NCBI Bookshelf). Milk-Alkali Syndrome (StatPearls, NCBI Bookshelf accession NBK557500) - the chapter text as NLM's own record serves it; the chapter page itself answers a browser challenge, see notes. 2024. PMID 32491432. Read the source
5. Antimicrobial agents and chemotherapy. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study. 2026. PMID 41313173, DOI 10.1128/aac.00781-25. Read the source
6. Clinical pharmacokinetics. Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses. 2024. PMID 38807006, DOI 10.1007/s40262-024-01377-0. Read the source
7. Clinical Pharmacokinetics. Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses - Discussion, 'Type of Dietary Intervention', the four consecutive paragraphs on antacids and mineral supplements, including the two that scope calcium's effect on the other quinolones; the source's own table and figure cross-references are kept, its numeric citation markers are not. 2024. PMID 38807006, DOI 10.1007/s40262-024-01377-0. Read the source
8. Therapeutics and clinical risk management. Medications and Food Interfering with the Bioavailability of Levothyroxine: A Systematic Review. 2023. PMID 37384019, DOI 10.2147/tcrm.s414460. Read the source
9. Therapeutics and Clinical Risk Management. Medications and Food Interfering with the Bioavailability of Levothyroxine: A Systematic Review - the 'Calcium Supplements' subsection, all three of its paragraphs, held whole and in document order. 2023. PMID 37384019, DOI 10.2147/TCRM.S414460. Read the source
10. The American journal of clinical nutrition. High dietary calcium intakes reduce zinc absorption and balance in humans. 1997. PMID 9174476, DOI 10.1093/ajcn/65.6.1803. Read the source
11. Nutrition bulletin. Factors affecting iron absorption and the role of fortification in enhancing iron levels. 2023. PMID 37965925, DOI 10.1111/nbu.12643. Read the source
12. The Journal of nutrition. Meals and dephytinization affect calcium and zinc absorption in Nigerian children with rickets. 2009. PMID 19321589, DOI 10.3945/jn.108.101030. Read the source
13. DailyMed (US National Library of Medicine); labeler Haleon US Holdings LLC; NDC 0135-0118. TUMS ULTRA (calcium carbonate 1000 mg) chewable tablet - US Drug Facts label, sections Active ingredient through the FIRST Other information section. 2026. Read the source
14. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. Comparison of calcium citrate and calcium carbonate absorption in patients with a Roux-en-Y gastric bypass, sleeve gastrectomy, and one-anastomosis gastric bypass: a double-blind, randomized cross-over trial. 2025. PMID 39603923, DOI 10.1016/j.soard.2024.10.034. Read the source
15. Clinical Practice and Cases in Emergency Medicine. A Case Report of Milk-Alkali Syndrome Secondary to Excessive Antacid Use - the hospital-course paragraph reporting the calcium values and the furosemide dose. 2026. PMID 41666902, DOI 10.5811/cpcem.48354. Read the source
16. Clinical Practice and Cases in Emergency Medicine. A Case Report of Milk-Alkali Syndrome Secondary to Excessive Antacid Use - the Discussion paragraph on emergency management. 2026. PMID 41666902, DOI 10.5811/cpcem.48354. Read the source
17. Journal of internal medicine. Calcium supplements: benefits and risks. 2015. PMID 26174589, DOI 10.1111/joim.12394. Read the source
18. The New England journal of medicine. Calcium plus vitamin D supplementation and the risk of fractures. 2006. PMID 16481635, DOI 10.1056/nejmoa055218. Read the source
19. BMJ (Clinical research ed.). Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. 2010. PMID 20671013, DOI 10.1136/bmj.c3691. Read the source
20. Clinical practice and cases in emergency medicine. A Case Report of Milk-Alkali Syndrome Secondary to Excessive Antacid Use. 2026. PMID 41666902, DOI 10.5811/cpcem.48354. Read the source
21. Endocrine. L-thyroxine malabsorption due to calcium carbonate impairs blood pressure, total cholesterolemia, and fasting glycemia. 2019. PMID 30368654, DOI 10.1007/s12020-018-1798-7. Read the source
22. DailyMed, US National Library of Medicine (labeler-submitted SPL, setid f4786707, spl_version 21). TUMS ULTRA (calcium carbonate 1000 mg) chewable tablet - US Drug Facts label, the SECOND Other information section, headed "Other information– (Tropical Fruit and Assorted Fruit)", which carries the tartrazine colour-additive disclosure. 2026. Read the source
23. Scientific reports. Prospective uncontrolled clinical study shows rapid and long lasting relief of heartburn and acid related gastric discomfort with Refluthin. 2025. PMID 40335653, DOI 10.1038/s41598-025-98558-z. Read the source
24. BMC musculoskeletal disorders. The effects of combined calcium and vitamin D supplementation on bone mineral density and fracture risk in postmenopausal women with osteoporosis: a systematic review and meta-analysis of randomized controlled trials. 2025. PMID 41063100, DOI 10.1186/s12891-025-09089-7. Read the source
25. Current developments in nutrition. Calcium Supplements and Risk of CVD: A Meta-Analysis of Randomized Trials. 2023. PMID 37181938, DOI 10.1016/j.cdnut.2023.100046. Read the source
26. Annals of internal medicine. Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. 2016. PMID 27776362, DOI 10.7326/M16-1743. Read the source
27. Digestive diseases (Basel, Switzerland). Self-Management of Reflux-Like Symptoms: A Patient-Centered Decision-Making Approach. 2026. PMID 41875283, DOI 10.1159/000551414. Read the source
28. JAMA network open. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. 2019. PMID 31860103, DOI 10.1001/jamanetworkopen.2019.17789. Read the source
29. The Journal of international medical research. Antacids revisited: review on contemporary facts and relevance for self-management. 2022. PMID 35343261, DOI 10.1177/03000605221086457. Read the source
30. Digestive Diseases. Self-Management of Reflux-Like Symptoms: A Patient-Centered Decision-Making Approach - the 'Conflict of Interest Statement' and 'Funding Sources' sections, held whole and in document order. 2026. PMID 41875283, DOI 10.1159/000551414. Read the source
31. Cureus. Milk-Alkali Syndrome in the Context of Pulmonary Tuberculosis: An Overlooked Aetiology of Hypercalcaemia. 2025. PMID 41216250, DOI 10.7759/cureus.96369. Read the source